TCM
ALNY icon

Traynor Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Traynor Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Sell
10,458
-2,134
-17% -$644K 0.14% 80
2026
Q1 		$3.98M Buy
12,592
+1,022
+9% +$348K 0.23% 66
2025
Q4 		$4.6M Buy
11,570
+697
+6% +$308K 0.25% 60
2025
Q3 		$4.96M Buy
10,873
+668
+7% +$272K 0.28% 54
2025
Q2 		$3.29M Buy
10,205
+372
+4% +$103K 0.23% 55
2025
Q1 		$2.66M Buy
9,833
+483
+5% +$124K 0.22% 65
2024
Q4 		$2.2M Buy
9,350
+2,101
+29% +$553K 0.15% 78
2024
Q3 		$1.99M Buy
+7,249
New +$1.89M 0.12% 79
2017
Q3 		– Sell
-6,479
Closed -$516K – 169
2017
Q2 		$516K Buy
6,479
+1,200
+23% +$76.7K 0.25% 81
2017
Q1 		$280K Buy
+5,279
New +$244K 0.16% 116

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Traynor Capital Management's ALNY Position: Q2 2026 in Review

Traynor Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 17% in Q2 2026, selling an estimated $644K and leaving 10,458 shares worth $3.15M. The position accounts for 0.14% of the portfolio, ranked #80.

Traynor Capital Management first reported a position in ALNY in Q1 2017 and has held it in 10 quarters since. The position peaked at $4.96M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Traynor Capital Management held 10,458 shares of Alnylam Pharmaceuticals worth $3.15M as of Q2 2026.
  • Traynor Capital Management sold 2,134 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $644K.
  • Alnylam Pharmaceuticals made up 0.14% of Traynor Capital Management's portfolio in Q2 2026, its #80 holding.
  • Traynor Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2017 and has held it in 10 quarters since.
  • Traynor Capital Management's Alnylam Pharmaceuticals position peaked at $4.96M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Traynor Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.